Group 1 - The legal opinion letter confirms the legitimacy of the 2025 First Extraordinary General Meeting of Guangdong Tai'enkang Pharmaceutical Co., Ltd. [1][3] - The meeting was convened on August 20, 2025, following the approval of the board of directors on August 4, 2025, with proper notification to shareholders [2][3] - A total of 227 participants attended the meeting, representing 42,134,395 shares, which is 9.9488% of the total shares as of the record date [3][4] Group 2 - The meeting was chaired by Chairman Zheng Hanjie, and the procedures followed were in accordance with the Company Law and relevant regulations [3][5] - Voting was conducted through both on-site and online methods, with results announced immediately after the voting process [5][6] - The resolutions passed included significant support from shareholders, with over 99.9% approval for key proposals [6][7] Group 3 - The legal opinion concludes that the meeting's convening, procedures, and voting were all compliant with applicable laws and the company's articles of association, rendering the resolutions valid [7][8] - The legal opinion letter is to be submitted alongside other disclosure materials related to the meeting [7][9]
泰恩康: 国浩律师（深圳）事务所关于广东泰恩康医药股份有限公司2025年第一次临时股东大会法律意见书